Focus: Opko Health is a diversified diagnostics and therapeutics company with ~$863M in FY2025 revenue, operating across infectious diseases, vaccines, and specialty biologics with a public market presence (ticker: OPK).
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Opko Health to get notified when they start hiring — the background below is worth knowing for when they do.
Flagship diagnostics asset supporting company's diagnostics segment; no patent cliff imminent and revenue-generating as of FY2025.
Help build intelligence for Opko Health
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Opko Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Approved product with Phase 4 data generation ongoing; mature asset with limited growth trajectory.
Commercial-stage product in large ophthalmic market; clinical efficacy demonstrated but market competition significant.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - TradingView
Here's Why You Should Retain OPK Stock in Your Portfolio for Now TradingView
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook - AD HOC NEWS
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook AD HOC NEWS
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus - AD HOC NEWS
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus AD HOC NEWS
8-K Filing: Profound Medical Corp. (PROF) (CIK 0001628808) — EXHIBIT 99.1
EXHIBIT 99.1
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
OPKO Health receives 15% stake in Nicoya for China drug rights StreetInsider
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - TradingView
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y TradingView
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo